CCM
DGX icon

CTC Capital Management’s Quest Diagnostics DGX Stock Holding History

CTC Capital Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,500
Closed -$465K – 130
2022
Q2 		$465K Buy
+3,500
New +$477K 0.51% 39

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CTC Capital Management's DGX Position: Q3 2022 in Review

CTC Capital Management sold out of Quest Diagnostics (DGX) in Q3 2022, closing a stake of 3,500 shares — an estimated $465K sold.

CTC Capital Management first reported a position in DGX in Q2 2022 and held it in 1 quarter. The position peaked at $465K in Q2 2022. 808 funds tracked by Wall St. Rank hold DGX as of Q3 2022.

  • CTC Capital Management reported no remaining Quest Diagnostics position as of Q3 2022 after selling out during the quarter.
  • CTC Capital Management sold 3,500 Quest Diagnostics shares in Q3 2022, an estimated $465K.
  • CTC Capital Management first reported a position in Quest Diagnostics in Q2 2022 and held it in 1 quarter.
  • CTC Capital Management's Quest Diagnostics position peaked at $465K in Q2 2022.
  • 808 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2022.

Based on CTC Capital Management's 13F filing for Q3 2022, filed 20 Oct 2022.